NCT01334242

A Study to Determine the Pharmacodynamics of LX4211 Relative to Meals in Healthy Subjects

A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Determine the Pharmacodynamics of LX4211 Relative to Meals in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 14 (estimated)
• Sponsor: Lexicon Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The primary purpose of this study is to evaluate the pharmacodynamics of LX4211 relative to meals in healthy subjects.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Schedule A	Dosing 1 hour before breakfast
DRUG	Schedule B	Dosing 0.5 hour before breakfast
DRUG	Schedule C	Dosing immediately before breakfast
DRUG	Schedule D	Dosing immediately before lunch
DRUG	Schedule E	Split dose, dosing 1 hour before breakfast and dinner

Timeline

• Start date: 2011-03-01
• Primary completion: 2011-04-01
• First posted: 2011-04-13
• Last updated: 2011-05-19

Locations

1 site across 1 country: United States